Get the Stockscreener App
2.76
0.36%
-0.01
After Hours:
2.76
Calcimedica Inc stock is traded at $2.76, with a volume of 64,967.
It is down -0.36% in the last 24 hours and down -20.00% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
See More
Previous Close:
$2.77
Open:
$2.81
24h Volume:
64,967
Relative Volume:
1.12
Market Cap:
$37.21M
Revenue:
-
Net Income/Loss:
$-13.59M
P/E Ratio:
-0.0772
EPS:
-35.74
Net Cash Flow:
$-19.79M
1W Performance:
+1.10%
1M Performance:
-20.00%
6M Performance:
-46.92%
1Y Performance:
-10.04%
1-Day Range:
$2.76
$2.89
1-Week Range:
$2.6702
$2.90
52-Week Range:
$2.05
$8.38
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
2.76 | 37.21M | 0 | -13.59M | -19.79M | -1.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - The Eastern Progress Online
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - The Eastern Progress Online
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Graybug Vision stock hits 52-week low at $2.65 amid market challenges - Investing.com Canada
CalciMedica director Fred Middleton buys $12,720 in stock By Investing.com - Investing.com Canada
CalciMedica director Fred Middleton buys $12,720 in stock - Investing.com
Atria Investments Inc Purchases 15,296 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica to Present CRAC Channel Therapy Updates at Piper Sandler Healthcare Conference | CALC Stock News - StockTitan
CalciMedica Announces Presentations at Upcoming Medical Meetings - PR Newswire
Insiders Bet Big on These Small Cap Stocks - MSN
CalciMedica Launches $10M+ Public Stock Offering BIOPHARMA: Propelling Calcium-Based Drug Platform By JENNIFER KASTNER - San Diego Business Journal
CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright - Defense World
CalciMedica reports Q3 EPS (50c), consensus (50c) - TipRanks
CalciMedica's Auxora Shows 100% Risk Reduction in Respiratory Failure, Extends Cash Runway | CALC Stock News - StockTitan
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates - PR Newswire
CalciMedica Appoints Stephen Bardin as New CFO - TipRanks
CalciMedica Appoints Chief Financial Officer - Contract Pharma
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer - Citizentribune
CalciMedica director Fred Middleton acquires shares valued at $404,040 - Investing.com India
CalciMedica director Fred Middleton acquires shares valued at $404,040 By Investing.com - Investing.com Australia
CalciMedica sees significant stock purchase by Sanderling Ventures - Investing.com India
H.C. Wainwright cuts CalciMedica stock target to $16, keeps Buy rating - Investing.com Australia
Graybug Vision Suspends Stock Offering Amid Proposed Public Offering of CalciMedica - Defense World
Calcimedica director Robert Wilson acquires $199,998 in stock - Investing.com India
CalciMedica's chief business officer Eric Roberts acquires $199,998 in stock By Investing.com - Investing.com Australia
CalciMedica CEO Rachel Leheny acquires $75,000 in common stock By Investing.com - Investing.com Australia
Calcimedica director Robert Wilson acquires $199,998 in stock By Investing.com - Investing.com Australia
Director Robert Wilson Acquires 53,333 Shares of CalciMedica Inc (CALC) - GuruFocus.com
CalciMedica CEO Rachel Leheny acquires $75,000 in common stock - Investing.com
CalciMedica's chief business officer Eric Roberts acquires $199,998 in stock - Investing.com
CalciMedica announces proposed public offering of common stock - MSN
CalciMedica Announces Pricing of Public Offering of Common Stock - StockTitan
CalciMedica launches public stock offering - Investing.com
CalciMedica launches public stock offering By Investing.com - Investing.com UK
CalciMedica Announces Proposed Public Offering of Common Stock - StockTitan
CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Decline in Short Interest - MarketBeat
CalciMedica’s Promising Phase 2b Trial Results for Auxora - TipRanks
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):